Company Filing History:
Years Active: 2019-2025
Title: Innovations of Zoila Areli Lopez Bujanda
Introduction
Zoila Areli Lopez Bujanda is a notable inventor based in Bethesda, MD (US). She has made significant contributions to the field of molecular biology, particularly in the detection of tumor DNA. With a total of 2 patents, her work has the potential to impact cancer diagnostics and treatment.
Latest Patents
Her latest patents include the "Quantitative multiplex methylation specific PCR method-CMethDNA." This innovative method quantitatively detects tumor DNA or other circulating DNAs in fluids such as serum or plasma at the lowest copy number. The cMethDNA method is unique compared to other PCR-based assays, as it incorporates a small number of copies of a synthetic polynucleotide standard (STDgene) added to an aliquot of patient serum. A cocktail of standards for multiple genes of interest (TARGETgene) is also included. After total DNA purification, a multiplex PCR is performed, co-amplifying the STDgene and TARGETgene with the same external primer set. The second nested PCR step involves real-time PCR, allowing for quantification of each gene in one well by two-color real-time PCR. This method represents a novel modification of the QM-MSP method, specifically designed for the quantitative detection of tumor DNA at the lowest copy number reported.
Career Highlights
Zoila works at The Johns Hopkins University, where she continues to advance her research in molecular diagnostics. Her innovative approaches have garnered attention in the scientific community, contributing to the understanding of cancer biology and diagnostics.
Collaborations
She collaborates with esteemed colleagues, including Saraswati Vaidyanathan Sukumar and Mary Jo Fackler, who contribute to her research endeavors.
Conclusion
Zoila Areli Lopez Bujanda's work exemplifies the intersection of innovation and healthcare, particularly in cancer diagnostics. Her contributions through her patents are paving the way for advancements in the detection of tumor DNA, which could significantly enhance patient outcomes.